Vogenx, Inc.
4-person clinical-stage biotech advancing mizagliflozin for post-bariatric hypoglycemia.
The call
Vogenx needs a clean IPO close and a strong EMERGE readout to survive, while Amylyx's avexitide already circulates in patients through expanded access.
Vogenx is a four-person company betting everything on a single medicine called mizagliflozin, licensed from another company, to treat dangerously low blood sugar that happens after gastric bypass surgery. The drug has been tested in over 500 patients so far, which gives Vogenx some legal protection, but that protection only matters if the medicine actually works when the final trial results come in this year. The company has almost no money in the bank and needs its planned stock market debut to raise $75 million just to survive, while a rival company called Amylyx is already letting patients access a competing treatment outside normal channels, and several other companies are racing to solve the same problem. The entire bet hinges on one thing: whether the Phase 2b trial shows mizagliflozin works well enough to move forward, because without that success and without the IPO money landing in the bank, the company simply cannot continue.
Why
01
AI pressure: None apparent. No AI product competes here; Vogenx's fate rests on trial biology and cash, not automation or software rivals. Could AI do the core job? Unlikely.
02
Bigger players: Amylyx Pharmaceuticals. Amylyx's avexitide already reaches PBH patients through an Expanded Access Program while Vogenx is still in Phase 2b. Could a giant copy it? Probably.
03
What protects it. Exclusive Kissei license plus over 500 dosed subjects across two completed Phase 2 trials give Vogenx real clinical data others lack.
What would change this call
Vogenx reports EMERGE Phase 2b topline results for mizagliflozin. Shows whether the drug works, the single event that determines the company's future.
Amylyx files an NDA or wins approval for avexitide in post-bariatric hypoglycemia. Shows a rival reaching market first, weakening Vogenx's competitive window.
VOGX completes its Nasdaq debut at or near the $11 to $13 per share range. Shows whether the IPO closed cleanly enough to fund the Phase 2b trial.
Amylyx files an NDA or wins approval for avexitide in post-bariatric hypoglycemia. Shows a rival reaching market first, weakening Vogenx's competitive window.
VOGX completes its Nasdaq debut at or near the $11 to $13 per share range. Shows whether the IPO closed cleanly enough to fund the Phase 2b trial.
Key numbers
- Cash on hand: $251,000
- IPO targets $75M at $11 to $13 per share
- Mizagliflozin dosed in 500+ subjects, 2 completed Phase 2 trials
Named risks
- Only $251,000 cash as of March 2026 makes the company dependent on IPO proceeds to survive.
- Single-asset, pre-revenue business with binary Phase 2b EMERGE trial outcome for mizagliflozin.
- Amylyx already running an Expanded Access Program for a rival PBH drug as of May 2026.
- IPO could be delayed, downsized, or priced below range given volatile 2026 small-float biotech market.
- Only 4 employees limits capacity to run trials, regulatory filings, and commercial buildout simultaneously.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Amylyx Pharmaceuticals | gaining on | Launched Expanded Access Program for avexitide in up to 250 PBH adults, May 2026, ahead of Vogenx Phase 2b |
| Rezolute | contesting | Ersodetug missed Phase 3 primary endpoint but showed CGM benefit in related hypoglycemia trial, May 2026 |
| Vanda Pharmaceuticals | contesting | Named by BioSpace as main PBH/gastroparesis competitor, July 2026, neither has FDA approval |
| MBX Biosciences | contesting | Developing imapextide (MBX 1416) in the same crowded PBH pipeline as of July 2026 |
| Gubra | contesting | AMX0318 partnered with Amylyx in PBH pipeline, per July 2026 market report |
Questions people ask
- Is Vogenx profitable?
- No. Vogenx is pre-revenue with a net loss of $1.446 million for fiscal 2025 and had only $251,000 in cash as of March 31, 2026, per its July 2026 S-1 filing, making it entirely dependent on its pending $75 million IPO to keep operating.
- Could AI replace Vogenx's drug development work?
- No. Vogenx's core asset is an exclusive worldwide license (excluding Japan, Korea, Taiwan) to mizagliflozin from Kissei Pharmaceutical, effective December 21, 2021, plus human trial data from over 500 dosed subjects. Drug approval requires human clinical trials and FDA review, a process AI cannot bypass.
- Who is Vogenx's biggest competitor?
- Amylyx Pharmaceuticals is the most advanced rival, having launched a US Expanded Access Program for its drug avexitide covering up to 250 adults with post-bariatric hypoglycemia in May 2026, ahead of Vogenx's own Phase 2b EMERGE trial for mizagliflozin.
- Who owns Vogenx?
- Vogenx, Inc. is privately held as of July 2026, incorporated in Delaware on February 5, 2021, and funded by an approximately $11 million Series A round closed January 28, 2022. It filed for a Nasdaq IPO under ticker VOGX on July 15, 2026, with no parent company identified.
- What is Vogenx's main drug candidate?
- Mizagliflozin, an orally administered, minimally absorbed small-molecule SGLT1 inhibitor licensed from Kissei Pharmaceutical. It has been dosed in over 500 subjects across 10 clinical studies and is in a Phase 2b trial called EMERGE for post-bariatric hypoglycemia as of July 2026.
- Will Vogenx's IPO succeed?
- Vogenx set IPO terms on July 28-29, 2026 to sell 6.25 million shares at $11-13 per share for roughly $75 million, implying a fully diluted valuation of about $173 million, with JonesTrading as sole bookrunner. Actual pricing and trading debut were not yet confirmed as of that date.
Timeline
- 2026-07-29Vogenx sets IPO terms: 6.25M shares at $11-13, targeting $75M gross proceeds
- 2026-07-16BioSpace names Amylyx and Vanda as main PBH/gastroparesis competitors
- 2026-07-15Vogenx files Form S-1 for Nasdaq IPO under ticker VOGX
- 2026-07-07Market report lists crowded PBH pipeline including Recordati, MBX, Confo, Gubra, Hanmi
- 2026-05-02Rezolute's ersodetug misses Phase 3 primary endpoint in hyperinsulinism trial
- 2026-05-01Amylyx launches US Expanded Access Program for avexitide in up to 250 PBH adults
- 2026-03-31Vogenx cash balance falls to $251,000
- 2024-04-02Vogenx completes dosing of last patient in Phase 2 study VGX-001-012 for PBH
- 2023-09-26Kissei exclusive license agreement amended
- 2022-01-28Vogenx closes approximately $11 million Series A round
- 2021-12-21Exclusive license agreement with Kissei for mizagliflozin becomes effective
- 2021-02-05Vogenx, Inc. incorporated in Delaware
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Form S-1 Vogenx, Inc. (2026-07-15)
- Vogenx, Clinical-Stage Metabolic Disease Therapeutics, Files for Nasdaq Capital Market IPO (2026-07-15)
- Vogenx 2026 Company Profile: Valuation, Funding & Investors
- Metabolic disorders biotech Vogenx sets terms for $75 million IPO (2026-07-29)
- Vogenx joins the IPO queue to fund phase 2-stage metabolic drug (2026-07-16)
- Management and Employees List
- Phase 2b biotech developing therapies for endocrine and metabolic disorders
- Exclusive License Agreement, dated as of December 21, 2021 (2023-09-26)
- Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno (2026-07-16)
- Vogenx Completes Dosing of Last Patient in Phase 2 Clinical Study of Mizagliflozin (2024-04-02)
- Post-Bariatric Hypoglycemia Market to Register Stunning Growth... (2026-07-07)
- Rezolute's Ersodetug Missed Primary Endpoint but Shows CGM Benefits in Hyperinsulinism Trial (2026-05-02)